ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO18

The Australasian Kidney Trials Network: Collaborating to Deliver Trial Results That Matter to the Kidney Community

Session Information

  • Informational Posters
    November 04, 2021 | Location: On-Demand, Virtual Only
    Abstract Time: 10:00 AM - 12:00 PM

Category: Educational Research

  • No subcategory defined

Authors

  • Robison, Laura, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Johnson, David W., The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Reidlinger, Donna, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Cho, Yeoung Jee, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Viecelli, Andrea K., The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Pascoe, Elaine, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Krishnasamy, Rathika, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia
  • Roberts, Matthew A., Eastern Health, Melbourne, Victoria, Australia
  • Collins, Michael G., Auckland District Health Board, Auckland, Auckland, New Zealand
  • Hawley, Carmel, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia

Group or Team Name

  • The Australasian Kidney Trials Network
Description

The Australasian Kidney Trials Network (AKTN), at The University of Queensland, Australia is a collaborative research group that designs and conducts investigator-initiated clinical trials with the aim of improving life for people with chronic kidney disease. Since its establishment in 2004, the AKTN has become a highly respected not for profit organisation having completed 11 trials including high impact trials such as FAVOURED, PEXIVAS and CKD-FIX. Eight trials are ongoing, and a record number of newly funded trials will start in 2021. Researchers and consumers from Australia and New Zealand with an interest in kidney care provide expertise on trial development and oversight. A key priority is building research capability and capacity, such as mentoring early career researchers and supporting smaller research sites in establishing their research portfolio. A range of innovative trial designs are used, such as pragmatic, registry-based, or adaptive to suit the trial setting, maximise recruitment and minimise burden for participants and site staff.

International collaborative partnerships via a network of networks enables the coordinating centre in each country to support trial operations in their region according to local requirements, then share strategies centrally to enhance trial quality and integrity.

Examples of international collaborative trials:

TEACH-PD: A pragmatic, registry-based, cluster-randomised controlled trial examining whether the use of TEACH-PD training modules for incident PD patients versus existing practices reduces the rate of PD-related infections. Data capture through national dialysis registries has greatly reduced trial data entry burden and allows easy integration into usual practice. Recruiting in Australia and New Zealand.

PHOSPHATE: A pragmatic, prospective, randomised trial to determine whether the currently recommended strategy of intensive serum phosphate reduction towards normal levels reduces the risk of fatal or non-fatal major cardiovascular events in people on dialysis. The broad inclusion criteria and flexible phosphate management strategy facilitates recruitment and retention of a generalisable population. Recruiting in Australia, New Zealand, Canada and the UK.

Funding

  • Medical Research Future Fund & National Health and Medical Research Council